Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Translational Neuroscience Optimization of GlyT1 Inhibitor

Trial Profile

Translational Neuroscience Optimization of GlyT1 Inhibitor

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PF 3463275 (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use
  • Acronyms NCATS

Most Recent Events

  • 01 Jun 2023 Results assessing whether whether co-administration of a GLYT1 inhibitor and computerized CT would have synergistic effects on cognitive impairments associated with schizophrenia , published in the Schizophrenia Research
  • 01 Mar 2023 Status changed from active, no longer recruiting to completed.
  • 06 Jan 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top